Calliditas Therapeutics AB (publ)

NASDAQ (USD): Calliditas Therapeutics AB (publ) (CALT)

Last Price

40.00

Today's Change

-0.04 (0.09%)

Day's Change

40.00 - 43.00

Trading Volume

9,795

Overview

Market Cap

1 Billion

Shares Outstanding

27 Million

Avg Volume

7,730

Avg Price (50 Days)

39.65

Avg Price (200 Days)

29.60

PE Ratio

-22.73

EPS

-1.76

Earnings Announcement

11-Nov-2024

Previous Close

40.04

Open

40.00

Day's Range

40.0 - 43.0

Year Range

15.25 - 43.0

Trading Volume

9,795

Price Change Highlight

1 Day Change

0.00%

5 Day Change

0.00%

1 Month Change

0.00%

3 Month Change

3.12%

6 Month Change

113.90%

Ytd Change

60.00%

1 Year Change

129.16%

3 Year Change

75.06%

5 Year Change

104.08%

10 Year Change

104.08%

Max Change

104.08%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment